Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences

Coronado Biosciences logo

BURLINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and CEO, will present at the following upcoming investor conferences:

  • Baird's 2013 Health Care Conference on Tuesday, September 10, 2013 at 2:55 PM ET. The conference will be held at The New York Palace on September 10-11, 2013.
  • Stifel Nicolaus 2013 Healthcare Conference on Thursday, September 12, 2013 at 11:30 AM ET. The conference will be held September 11-12, 2013 at the Four Seasons in Boston, MA. A webcast of the presentation will be available at on the Events & Webcasts page.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, including Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit

CONTACT: Lucy Lu, MD, Executive Vice President & Chief Financial Officer Coronado Biosciences, Inc. 781-652-4525; Marcy Nanus, Vice President The Trout Group, LLC. 646-378-2927; Susan Forman Dian Griesel Inc. 212-825-3210;

Source:Coronado Biosciences